Tyrosine Kinase Inhibitor Library Shows You Advanced Lingo . Now We Enter The Excitement

Poor reporting of medical treatment at discharge might reflect an underestimation of secondary prevention http://en.wikipedia.org/wiki/VAV2 in patients undergoing cardiac surgery or interventional procedures in head-to-head interventional trials. Thus, discussion of optimal revascularization procedure has to remain open, even in terms of concomitant medical treatment of patients. Additional Supporting Information may be found in the online version of this article. The authors have no funding, financial relationships, or conflicts of interest to disclose. The benefits of medical treatment for secondary prevention have been clearly demonstrated in patients with coronary artery disease, but optimal revascularization strategy is still under debate, particularly due to the results of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) trial.1 However, in SYNTAX, coronary artery bypass grafting (CABG) patients compared to percutaneous coronary intervention (PCI) patients were significantly undertreated with evidence-based medications for cardiovascular protection. Thus, the short outcome limits the interpretation for long-term outcome judgment in cardiovascular high-risk patients. Therefore, a systematic search of the literature regarding concomitant medical treatment in cardiovascular interventional head-to-head trials comparing CABG and PCI was http://www.selleckchem.com/GSK-3.html conducted by 2 independent reviewers. MEDLINE and Embase databases were searched for studies by using the following terms: ��coronary�� and ��angioplasty�� in combination with ��coronary artery bypass surgery�� and ��randomized controlled trial.�� Selection of references was performed in 2 steps. First, abstracts were excluded if they were about nonhuman data, letters, reviews, case reports, in a language other than English, trials with http://www.selleckchem.com/screening/tyrosine-kinase-inhibitor-library.html additional medical treatment arm. Second, articles without information on recommended medical treatment for cardiovascular secondary prevention such as statins, angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), ��-blockers, and platelet inhibitors were also excluded. Trials without a prospective design or randomization were not included. Conflicts between reviewers were resolved through discussion and rereview. Systematic research of the literature identified 2106 articles (Figure 1) of potential interest. After the first selection step, 118 articles remained. References for these articles are shown in the online supplement. Further selection excluded another 115 articles, of which 91 had to be excluded due to missing information on medical drug treatment. Only 3 of the 2106 trials reported medical treatment. The Randomized Intervention Treatment of Angina (RITA) trial published in 1988 included 1011 patients, reported baseline medication (platelet inhibitors and ��-blockers) without a significant intergroup difference.